lymphoma

[Blood] The authors demonstrated the feasibility of generating CD19-specific chimeric antigen receptor (CAR19) T-cells from HLA-matched donors of sibling allogeneic hematopoietic stem cell transplant patients via a simple and inexpensive method using the piggyBac transposon.

[Scientific Reports] Researchers found that acute lymphoblastic leukemia cells expressing MLL–AF4 fusion protein expressed high levels of lymphoid tissue-specific immunoproteasomes and were sensitive to pharmacologically relevant concentrations of specific immunoproteasome inhibitor ONX-0914.

[TG Therapeutics, Inc. (Globe Newswire, Inc.)] TG Therapeutics, Inc. announced that the FDA has accepted the Biologics License Application for Ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ®, their inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

[Clinical Cancer Research] The combination of AFM13 and IL-12/15/18 pre-activation of blood and cord-blood-derived NK cells was investigated in vitro and in vivo.

[Oncogene] Investigators focused on cancer-associated fibroblasts and their derived exosomes on the lymphoma microenvironment to uncover their clinical significance.

[Incyte, Inc. (BusinessWire, Inc)] Incyte and MorphoSys AG announced that the first patient has been dosed in the pivotal Phase III frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma.